[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@stocksdd Stocks DD
Stocks DD posts on X about $mreo, $nktr, $qure, $abvx the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXX -XX%
- X Month XXXXXX +331%
- X Months XXXXXX +909%
- X Year XXXXXX +586%
Mentions: X #
- X Week X -XX%
- X Month XX +260%
- X Months XX +557%
- X Year XX +125%
Followers: XXX #
- X Week XXX +0.51%
- X Month XXX -X%
- X Months XXX +0.68%
- X Year XXX -XXXX%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence finance XXXXX% cryptocurrencies XXX% stocks XXXX% currencies XXXX%
Social topic influence $mreo #4, $nktr #28, $qure #60, $abvx #24, $pali #11, $rare #33, $mltx 3.45%, $open 3.45%, $260m 3.45%, $245m XXXX%
Top accounts mentioned or mentioned by @javier944712106 @sharkbiotech @semodough @pharmdca @feldtinvesting @almightyzeeza @stephanklingel1 @wz2013 @wkissel @maximusholla @sanofi @revshark @ej23ny @mereobiopharma @tonythearena @darrenestes @avidresearch @medstudentinvst @andrews87261985 @tcfftk
Top assets mentioned uniQure N.V. (QURE) SuperRare (RARE) MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Open Custody Protocol (OPEN) AstraZeneca PLC (AZN) Novartis AG (NVS)
Top Social Posts #
Top posts by engagements in the last XX hours
"@bkfViking123 For technical traders $mreo $XXX is 100-day MA. Bullish if it breaks out with higher volume $XXXX is the next important price point as that would be 200-day MA $nktr $qure $abvx $mltx $pali $open"
X Link @stocksdd 2025-10-09T19:49Z XXX followers, 1362 engagements
"@medstudentinvst @DarrenEstes @Javier944712106 @AndrewS87261985 $Mreo is simple. mcap -cash= $260m. u get 1(or X if u incl Alvelostat) late stage assets & $245m mil paymt+2-digit US sales royalties to bottomline. They r lean. My guess is if a setrusu p3 trial fails they may try to salvage setrusu by designing a new trial w less variability"
X Link @stocksdd 2025-10-06T22:32Z XXX followers, XXX engagements
"@FeldtInvesting @TCFFTK $MREO buyout rumor from X years ago. These companies are their business partners $AZN $NVS $RARE $nktr $abvx $pali $qure"
X Link @stocksdd 2025-10-13T14:08Z XXX followers, XXX engagements
"@FeldtInvesting @TCFFTK They had the option to extend the trial to XX months but they did not. When asked why in the recent investor call they gave the foll reasons: p2 data and that total blinded total events in p3 were trending towards powering assumptions (maybe at ia2 cut off)"
X Link @stocksdd 2025-10-14T20:21Z XXX followers, XX engagements
"@medstudentinvst @DarrenEstes @Javier944712106 @AndrewS87261985 mgmt stated if X p3 trial hits stat sig & the other doesn't but end pt trends r good drug likely will get approved. Wth just X mth to go mgmt stated that in cosmic trial they're seeing much higher fracture rates in Bisphos group than in setrusumab. $MREO"
X Link @stocksdd 2025-10-06T17:42Z XXX followers, XXX engagements